ORCID Profile
0000-0002-9652-6351
Current Organisation
Universitat Autònoma de Barcelona
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 19-04-2021
DOI: 10.1038/S41592-021-01117-3
Abstract: Intrinsically disordered proteins, defying the traditional protein structure–function paradigm, are a challenge to study experimentally. Because a large part of our knowledge rests on computational predictions, it is crucial that their accuracy is high. The Critical Assessment of protein Intrinsic Disorder prediction (CAID) experiment was established as a community-based blind test to determine the state of the art in prediction of intrinsically disordered regions and the subset of residues involved in binding. A total of 43 methods were evaluated on a dataset of 646 proteins from DisProt. The best methods use deep learning techniques and notably outperform physicochemical methods. The top disorder predictor has F max = 0.483 on the full dataset and F max = 0.792 following filtering out of bona fide structured regions. Disordered binding regions remain hard to predict, with F max = 0.231. Interestingly, computing times among methods can vary by up to four orders of magnitude.
Publisher: Public Library of Science (PLoS)
Date: 27-01-2016
Publisher: Informa UK Limited
Date: 02-01-2016
Publisher: Cold Spring Harbor Laboratory
Date: 10-02-2023
DOI: 10.1101/2023.02.10.527650
Abstract: Oligomeric species populated during α-synuclein aggregation are considered key drivers of neurodegeneration in Parkinson’s disease. However, their structure and the molecular determinants driving their conversion to fibrils remain elusive. In this work, we determined the symmetry and architecture of α-synuclein oligomers, dissecting the conformational properties of in idual chains within these toxic assemblies. We demonstrate that the NAC domain is insufficient to promote oligomer to fibril conversion instead, this transition is controlled by a short α-synuclein N-terminal motif. A missense mutation causing early-onset Parkinson’s disease remodels this N-terminal region conformation, which results in a population of long-lived oligomers less susceptible to disaggregation by the human Hsp70 machinery. Our results provide a structural understanding of oligomer to amyloid conversion and identify targets for therapeutic intervention. α-Synuclein oligomers are symmetric and well-organized particles with a short N-terminal region controlling fibril conversion.
Publisher: Future Science Ltd
Date: 09-2015
DOI: 10.4155/FSO.15.43
Abstract: The main therapeutic and prophylactic tools against malaria have been locked for more than a century in the classical approaches of using drugs targeting metabolic processes of the causing agent, the protist Plasmodium spp., and of designing vaccines against chosen antigens found on the parasite's surface. Given the extraordinary resources exhibited by Plasmodium to escape these traditional strategies, which have not been able to free humankind from the scourge of malaria despite much effort invested in them, new concepts have to be explored in order to advance toward eradication of the disease. In this context, amyloid-forming proteins and peptides found in the proteome of the pathogen should perhaps cease being regarded as mere anomalous molecules. Their likely functionality in the pathophysiology of Plasmodium calls for attention being paid to them as a possible Achilles’ heel of malaria. Here we will give an overview of Plasmodium-encoded amyloid-forming polypeptides as potential therapeutic targets and toxic elements, particularly in relation to cerebral malaria and the blood–brain barrier function. We will also discuss the recent finding that the genome of the parasite contains an astonishingly high proportion of prionogenic domains.
No related grants have been discovered for Salvador Ventura.